Targeting the progesterone receptor in breast cancer: mind the short form!


 The pre-surgical window of opportunity trial (WOT), MIPRA, provides evidence that neoadjuvant treatment with the progesterone receptor (PR) antagonist Mifepristone (RU486) may benefit patients with ER+ breast cancer characterized by a high ratio of PR-A versus PR-B isoform (>1.5) suggesting that PR may be targeted in a subset of patients.